Director of Epidemiology
Teva Pharmaceutical Industries Ltd, Israel., Israel
Dr. Kaplan (PhD, BPharm) has served as Director of Epidemiology at Teva since December 2012. She leverages over than 25 years of pharmaccoepidemiology experience in regulatory and pharmaceutical industry with strong expertise in safety assessment, risk management, real world data, and registries. At Teva, she leads and oversees the execution of global post marketing requirements and post authorization safety studies (PASS), guiding them from inception to publication. She plays a key role in promoting the use of real-world evidence (RWE) for regulatory decision-making across various departments and designing epidemiologic and risk minimization strategies for regulatory submission. Her experience spans diverse therapeutic areas, including neurology, migraine, respiratory, oncology and women’s health.
Prior to joining Teva, she served as a senior pharmacoepidemiologist lead for 7 years within the Office of Surveillance and Epidemiology (OSE) at the US Food and Drug Administration (FDA). As a team leader for a group of epidemiologists in the Division, she provided oversight and guidance for their epidemiological reviews, leveraging her expertise in the field. Additionally, she reviewed and designed pharmacoepidemiological studies using real-world data (RWD) from various healthcare databases accessed through FDA-contracted data service partners.
Dr. Kaplan earned her PhD degree in Pharmaceutical Health Services Research with a major in pharmacoepidemiology from University of Maryland, USA. She also holds a Bachelor of Pharmacy (B.Pharm) degree from the Hebrew University in Jerusalem, Israel.